Quizartinib is a targeted therapy for acute myeloid leukemia caused by specific gene mutations. It is mainly used to treat relapsed or refractory FLT3-ITD mutation-positive AML and works by inhibiting FLT3 kinase activity. This article will introduce the key information of Quizartinib in detail from three aspects: indications, dosage and adverse reactions, to help patients fully understand this drug.

Indications of Quizartinib

The main indication of Quizartinib is relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia (AML).

FLT3-ITD mutation and AML

FLT3-ITD mutation causes continuous activation of FLT3 kinase, promoting the proliferation and survival of leukemia cells. Quizartinib can selectively inhibit FLT3, thereby blocking abnormal signal transduction and inhibiting the growth of leukemia cells.

Applicable population

Quizartinib is suitable for adult patients, especially those with FLT3-ITD mutation-positive AML who have poor response to traditional chemotherapy or relapse of the disease. It provides these patients with the possibility of prolonging survival and improving quality of life.

The indications of Quizartinib focus on its value as a targeted therapy, bringing new options to AML patients with specific gene mutations.

Usage and Dosage of Quizartinib

The dosage of Quizartinib must strictly follow the doctor's instructions. Its dosage form is white film-coated tablets, and the recommended dose is adjusted in stages to adapt to the individual differences of patients.

Initial dose and adjustment

The recommended oral dose for adults is 26.5 mg once a day for two weeks. If there are no serious adverse reactions, the dose can be increased to 53 mg once a day. Depending on the patient's tolerance, the doctor may adjust the dose appropriately.

Medication for special populations

Quizartinib should be used with caution in patients with impaired liver function. The difference in medication between elderly and young patients is not obvious, but close monitoring is required. The effectiveness of pediatric patients has not been fully established and needs to be used under the guidance of a doctor.

Rational use of Quizartinib is the key to successful treatment, and understanding its possible adverse reactions is equally important.

Adverse reactions of Quizartinib

Quizartinib may cause a variety of adverse reactions during treatment. Patients need to closely monitor their physical condition under the guidance of a doctor and deal with abnormal conditions in a timely manner.

Common adverse reactions

Adverse reactions with an incidence of ≥10% include QT interval prolongation, thrombocytopenia, neutropenia, anemia, leukopenia, febrile neutropenia, nausea, vomiting, diarrhea and asthenia. These reactions are mostly mild to moderate and can be relieved by symptomatic treatment.

Serious adverse reactions

QT interval prolongation is one of the serious adverse reactions of Quizartinib, and regular ECG monitoring is required. Bone marrow suppression and bleeding risks should also be vigilant, and regular blood routine examinations are essential.

Precautions and monitoring

ECG and electrolyte levels should be checked before medication, and regular review should be conducted during medication. For pregnant women, breastfeeding women and patients with fertility needs, risks and benefits should be strictly assessed and necessary contraceptive measures should be taken.

Understanding the adverse reactions of Quizartinib can help patients and doctors better manage the treatment process and balance the efficacy. Through scientific medication and close monitoring, patients can benefit to the greatest extent.